Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcipotriol + LEO 27989 is a topical combination therapy investigated for the treatment of plaque psoriasis. Calcipotriol (also known as calcipotriene) is a synthetic vitamin D3 analog that acts by binding to the vitamin D receptor, modulating gene transcription involved in cell differentiation and proliferation, and suppressing Th1/Th17-mediated inflammation in psoriatic lesions. LEO 27989 is an investigational small molecule developed by LEO Pharma; its precise mechanism of action has not been publicly disclosed but it has been studied for anti-psoriatic effects in combination with calcipotriol. The combination aims to enhance efficacy against immune-mediated skin diseases such as psoriasis vulgaris[2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcipotriol + LEO 27989.